TALANX AG

Discover how Talanx AG’s stake in HMNC Brain Health’s ketamine‑based depression therapy signals insurers’ shift to high‑growth biopharma and ESG‑aligned returns.

Discover why Talanx AG’s record profit didn’t lift its shares and the impact of BlackRock’s rising stake and derivative holdings on governance and investor confidence.

MDAX weekly review: Talanx AG’s slight decline shows resilience amid market volatility. Discover how regulatory shifts, climate risk, and digital strategy shape its outlook.

BlackRock’s new stake in Talanx signals confidence in the German insurer, while the share’s modest dip amid MDAX turbulence highlights its resilience and potential value for investors.

MDAX volatility in May 2026: Talanx AG’s modest drop amid insurance sector pressure, yet long‑term upside and a new market‑capitalisation milestone suggest resilient mid‑cap growth.

Explore Talanx AG’s recent stock dip, long‑term growth, governance concerns, and hidden risks in the German insurance market. Uncover what investors and policyholders need to know for smarter decisions.

Discover how Talanx AG’s €1 billion bond issuance and Mexican acquisition boost its balance sheet and expand market reach, positioning the insurer for future growth.

Explore Talanx AG’s May 2026 performance: modest share trends, rising dividend, and its strategic niche focus amid Germany’s evolving insurance landscape.

Corporate Analysis: Talanx AG tops 2026 Q1 forecasts, boosting earnings by 28 % and raising dividends, showing how disciplined risk and capital strategy drives growth.

Read how Talanx AG beat Q1 profit expectations, boosted 23% YoY, and what the 2026 surplus target and BlackRock stake mean for investors.